Loading...

We've got a brand new version of Simply Wall St! Try it out

Plus Products

CNSX:PLUS
Snowflake Description

High growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PLUS
CNSX
CA$173M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Plus Products Inc. manufactures cannabis products in California. The last earnings update was 24 days ago. More info.


Add to Portfolio Compare Print
  • Plus Products has significant price volatility in the past 3 months.
PLUS Share Price and Events
7 Day Returns
5.7%
CNSX:PLUS
-5.9%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
-
CNSX:PLUS
-46.7%
CA Pharmaceuticals
-0.1%
CA Market
PLUS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Plus Products (PLUS) 5.7% 8.3% 35.6% - - -
CA Pharmaceuticals -5.9% -3.4% -24.8% -46.7% 217.3% 286.4%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • No trading data on PLUS.
  • No trading data on PLUS.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Plus Products undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Plus Products to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Plus Products.

CNSX:PLUS Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7%
Perpetual Growth Rate 10-Year CA Government Bond Rate 1.9%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for CNSX:PLUS
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CA Govt Bond Rate 1.9%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.7
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.698 (1 + (1- 26.5%) (13.29%))
0.844
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.84
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.95% + (0.844 * 5.96%)
6.97%

Discounted Cash Flow Calculation for CNSX:PLUS using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Plus Products is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

CNSX:PLUS DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.97%)
2020 0.68 Analyst x2 0.64
2021 1.49 Analyst x1 1.30
2022 1.02 Analyst x1 0.83
2023 13.58 Analyst x1 10.37
2024 22.34 Est @ 64.45% 15.95
2025 32.54 Est @ 45.7% 21.72
2026 43.15 Est @ 32.57% 26.91
2027 53.23 Est @ 23.38% 31.04
2028 62.26 Est @ 16.95% 33.94
2029 70.01 Est @ 12.45% 35.67
Present value of next 10 years cash flows $178.00
CNSX:PLUS DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $70.01 × (1 + 1.95%) ÷ (6.97% – 1.95%)
$1,419.64
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,419.64 ÷ (1 + 6.97%)10
$723.39
CNSX:PLUS Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $178.00 + $723.39
$901.39
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $901.39 / 35.79
$25.19
CNSX:PLUS Discount to Share Price
Calculation Result
Exchange Rate USD/CAD
(Reporting currency to currency of CNSX:PLUS)
1.326
Value per Share
(CAD)
= Value per Share in USD x Exchange Rate (USD/CAD)
= $25.19 x 1.326
CA$33.4
Value per share (CAD) From above. CA$33.40
Current discount Discount to share price of CA$4.84
= -1 x (CA$4.84 - CA$33.40) / CA$33.40
85.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Plus Products is available for.
Intrinsic value
>50%
Share price is CA$4.84 vs Future cash flow value of CA$33.4
Current Discount Checks
For Plus Products to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Plus Products's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Plus Products's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Plus Products's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Plus Products's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:PLUS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in USD $-0.57
CNSX:PLUS Share Price ** CNSX (2019-09-20) in CAD CA$4.84
CNSX:PLUS Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.754 $3.65
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.3x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Plus Products.

CNSX:PLUS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:PLUS Share Price ÷ EPS (both in USD)

= 3.65 ÷ -0.57

-6.36x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Plus Products is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Plus Products is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Plus Products's expected growth come at a high price?
Raw Data
CNSX:PLUS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.36x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
114.9%per year
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Plus Products, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Plus Products's assets?
Raw Data
CNSX:PLUS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in USD $0.80
CNSX:PLUS Share Price * CNSX (2019-09-20) in CAD CA$4.84
CNSX:PLUS Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.754 $3.65
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.36x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:PLUS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:PLUS Share Price ÷ Book Value per Share (both in USD)

= 3.65 ÷ 0.80

4.56x

* Primary Listing of Plus Products.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Plus Products is overvalued based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Plus Products's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Plus Products has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Plus Products expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
114.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Plus Products expected to grow at an attractive rate?
  • Plus Products's earnings growth is expected to exceed the low risk savings rate of 1.9%.
Growth vs Market Checks
  • Plus Products's earnings growth is expected to exceed the Canada market average.
  • Plus Products's revenue growth is expected to exceed the Canada market average.
Annual Growth Rates Comparison
Raw Data
CNSX:PLUS Future Growth Rates Data Sources
Data Point Source Value (per year)
CNSX:PLUS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 114.9%
CNSX:PLUS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 83.1%
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.7%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:PLUS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:PLUS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 122 22 1
2020-12-31 75 1 0 3
2019-12-31 19 -10 -15 2
2019-09-22
CNSX:PLUS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-06-30 13 -14 -14
2019-03-31 11 -9 -9
2018-12-31 8 -5 -7
2018-09-30 5 -5 -5
2018-06-30 3 -4 -5
2018-03-31 2 -3 -4
2017-12-31 1 -3 -3
2016-12-31 0 -1 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Plus Products's earnings are expected to grow significantly at over 20% yearly.
  • Plus Products's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:PLUS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Plus Products Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:PLUS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.44 0.44 0.44 1.00
2020-12-31 0.01 0.04 -0.03 2.00
2019-12-31 -0.38 -0.38 -0.38 1.00
2019-09-22
CNSX:PLUS Past Financials Data
Date (Data in USD Millions) EPS *
2019-06-30 -0.57
2019-03-31 -0.49
2018-12-31 -0.48
2018-09-30 -0.34
2018-06-30 -0.35
2018-03-31 -0.50
2017-12-31 -0.22
2016-12-31 -0.07

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Plus Products will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Plus Products's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Plus Products has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Plus Products performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Plus Products's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Plus Products does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Plus Products's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Plus Products's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Plus Products's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Plus Products Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:PLUS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 12.73 -13.53 14.18 0.14
2019-03-31 10.74 -9.14 10.12 0.01
2018-12-31 8.36 -6.84 7.60 0.00
2018-09-30 5.40 -5.29 5.51 0.00
2018-06-30 3.19 -4.73 4.46 0.01
2018-03-31 1.77 -3.97 3.45 0.01
2017-12-31 1.07 -3.06 2.43 0.02
2016-12-31 0.07 -0.71 0.35

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Plus Products has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Plus Products has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Plus Products improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Plus Products's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Plus Products has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Plus Products's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Plus Products's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Plus Products is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Plus Products's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Plus Products's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Plus Products Company Filings, last reported 2 months ago.

CNSX:PLUS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 26.22 16.15 34.11
2019-03-31 30.32 10.78 35.58
2018-12-31 25.68 0.00 22.40
2018-09-30 13.74 0.00 11.14
2018-06-30 5.28 0.63 3.77
2018-03-31 0.78 0.60 0.15
2017-12-31 0.78 0.60 0.15
2016-12-31 -0.11 0.43 0.27
  • Plus Products's level of debt (61.6%) compared to net worth is high (greater than 40%).
  • Unable to establish if Plus Products's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Plus Products has sufficient cash runway for 2.1 years based on current free cash flow.
  • Unable to confirm if Plus Products has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Plus Products's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Plus Products has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Plus Products's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Plus Products dividends.
If you bought CA$2,000 of Plus Products shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Plus Products's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Plus Products's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:PLUS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CNSX:PLUS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2019-09-22

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Plus Products has not reported any payouts.
  • Unable to verify if Plus Products's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Plus Products's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Plus Products has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Plus Products's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Plus Products afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Plus Products has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Plus Products's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jake Heimark
COMPENSATION $472,242
CEO Bio

Mr. Jacob F. Heimark, also known as Jake, serves as Chief Executive Officer and Director at Plus Products Holdings Inc. Mr. Heimark serves as Co-Founder and Chief Executive Officer at Plus Products Inc and serves as its Director since July 24, 2018.

CEO Compensation
  • Insufficient data for Jake to compare compensation growth.
  • Jake's remuneration is higher than average for companies of similar size in Canada.
Management Team Tenure

Average tenure of the Plus Products management team in years:

0.4
Average Tenure
  • The average tenure for the Plus Products management team is less than 2 years, this suggests a new team.
Management Team

Craig Heimark

TITLE
Chairman
COMPENSATION
$324K
AGE
63
TENURE
0.4 yrs

Jake Heimark

TITLE
Co-Founder
COMPENSATION
$472K

Jennifer Tung

TITLE
Chief Risk Officer
COMPENSATION
$162K

Jon Paul

TITLE
Chief Financial Officer
TENURE
0.4 yrs

Jessica Bornn

TITLE
Director of Investor Relations

Marc Seguin

TITLE
Chief Revenue Officer
TENURE
0.4 yrs
Board of Directors Tenure

Average tenure of the Plus Products board of directors in years:

1.2
Average Tenure
  • The average tenure for the Plus Products board of directors is less than 3 years, this suggests a new board.
Board of Directors

Craig Heimark

TITLE
Chairman
COMPENSATION
$324K
AGE
63
TENURE
1.2 yrs

Jake Heimark

TITLE
Co-Founder
COMPENSATION
$472K
TENURE
1.2 yrs

Matt Schmidt

TITLE
Independent Director
COMPENSATION
$24K
TENURE
1.5 yrs

Sandy Posa

TITLE
Independent Director
COMPENSATION
$22K
TENURE
1.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
X
Management checks
We assess Plus Products's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Plus Products has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Why Plus Products Inc. (CNSX:PLUS) Could Be Your Next Investment

If you're interested in understanding beyond my broad commentary, take a look at the report on Plus Products here. … This indicates that PLUS has sufficient cash flows and proper cash management in place, which is a key determinant of the company’s health. … CNSX:PLUS Past and Future Earnings, July 3rd 2019 Next Steps: For Plus Products, I've put together three important factors you should further examine: Historical Performance: What has PLUS's returns been like over the past?

Simply Wall St -

Can We See Significant Insider Ownership On The Plus Products Inc. (CNSX:PLUS) Share Register?

Plus Products is a smaller company with a market capitalization of CA$110m, so it may still be flying under the radar of many institutional investors. … See our latest analysis for Plus Products CNSX:PLUS Ownership Summary, May 30th 2019 What Does The Lack Of Institutional Ownership Tell Us About Plus Products? … Insider Ownership Of Plus Products While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders.

Simply Wall St -

Company Info

Description

Plus Products Inc. manufactures cannabis products in California. The company offers cannabis-infused edibles to the regulated medicinal and adult-use, or recreational markets. It sells products under the PLUS brand to dispensaries and delivery service customers. The company was incorporated in 2018 and is headquartered in Vancouver, Canada.

Details
Name: Plus Products Inc.
PLUS
Exchange: CNSX
Founded: 2018
CA$173,216,833
35,788,602
Website: http://www.plusproducts.com
Address: Plus Products Inc.
1500 – 1055 West Georgia Street,
Vancouver,
British Columbia, V6E 4N7,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX PLUS Subordinate Voting Shares Canadian National Stock Exchange CA CAD 26. Oct 2018
OTCPK PLPR.F Subordinate Voting Shares Pink Sheets LLC US USD 26. Oct 2018
DB 0T1 Subordinate Voting Shares Deutsche Boerse AG DE EUR 26. Oct 2018
Number of employees
Current staff
Staff numbers
0
Plus Products employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:48
End of day share price update: 2019/09/20 00:00
Last estimates confirmation: 2019/09/18
Last earnings filing: 2019/08/29
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.